tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Arcus Biosciences price target raised to $16 from $14 at Goldman Sachs
PremiumThe FlyArcus Biosciences price target raised to $16 from $14 at Goldman Sachs
30d ago
Arcus Biosciences price target raised to $35 from $33 at Wedbush
Premium
The Fly
Arcus Biosciences price target raised to $35 from $33 at Wedbush
1M ago
Arcus Biosciences price target raised to $56 from $54 at Citi
Premium
The Fly
Arcus Biosciences price target raised to $56 from $54 at Citi
1M ago
Arcus Biosciences Advances Phase 3 Trial for Renal Cell Carcinoma
PremiumCompany AnnouncementsArcus Biosciences Advances Phase 3 Trial for Renal Cell Carcinoma
1M ago
Arcus Biosciences’ Promising Phase 1 Study on Renal Cell Carcinoma
Premium
Company Announcements
Arcus Biosciences’ Promising Phase 1 Study on Renal Cell Carcinoma
1M ago
Taiho exercises option to develop, commercialize casdatifan in Japan, Asia
Premium
The Fly
Taiho exercises option to develop, commercialize casdatifan in Japan, Asia
1M ago
Arcus Biosciences price target raised to $39 from $32 at Truist
PremiumThe FlyArcus Biosciences price target raised to $39 from $32 at Truist
2M ago
Arcus Biosciences’ Casdatifan Shows Superior Efficacy and Safety in ccRCC Treatment, Supporting Buy Rating
Premium
Ratings
Arcus Biosciences’ Casdatifan Shows Superior Efficacy and Safety in ccRCC Treatment, Supporting Buy Rating
2M ago
Arcus Biosciences: Promising Efficacy and Manageable Safety Profile Drive Buy Rating
Premium
Ratings
Arcus Biosciences: Promising Efficacy and Manageable Safety Profile Drive Buy Rating
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100